a study on SDI-DLB concerning to diagnose DLB and assess benefit for Donepezil : Study 1
Not Applicable
- Conditions
- DLB
- Registration Number
- JPRN-UMIN000018889
- Lead Sponsor
- Promedico Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
Not provided
Exclusion Criteria
1)dozed antidementia drugs except Donepezil within 12 weeks before informed consent 2)bed ridden 3)with severe impairment of visual acuity, auditory sensor and/or communication 4)with neurological degenerative disease except for DLBV criteria, schizophrenia, bipolar disorder and major depression 5)with delirium due to abuse of alcohol, drugs, metabolic toxicity and inflammation
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The correlation between SDI-DLB scores and scores of MMSE, PSMS and EQ-5D.
- Secondary Outcome Measures
Name Time Method The correlation between SDI-DLB scores and scores of MMSE, PSMS and EQ-5D.